Advanced biliary tract cancers have poor prognosis and emerging therapies focus on combining conventional chemotherapeutic agents with targeted compounds in the hope of obtaining more active and well tolerated combinations. The ERK pathway is frequently activated in biliary cancer and it has the potential to promote tumor growth and chemotherapy resistance. Our findings show that the antitumor effect of combined gemcitabine with the MEK inhibitor AZD6244 is strongly schedule-dependent. Concurrent administration of these two agents resulted in sub-additive or antagonistic effect, whereas enhanced effect over single agents was observed when gemcitabine was given following a 48hr interruption in AZD6244 dosing. Our study also provides a mechanistic explanation for this observation that delayed entry into S phase during MEK inhibition antagonizes the effects of the S-phase specific agent gemcitabine against biliary cancers. These observations have important implications regarding rational combination therapy schedules using these two agents. 4 be more effective in the clinic using sequential rather than simultaneous dosing protocols.
Introduction
Cancers arising in the biliary tract, consisting of the intra-and extra-hepatic bile ducts and the gallbladder, remain a major challenge to surgical, medical, and radiation oncologists. The large majority of these tumors are not resectable at the time of initial diagnosis and the overall prognosis is poor, with less than 5% survival rate at 5 years (1, 2) . Chemotherapy has limited activity, and gemcitabine appears to be one of the most active single agents (2) . A phase III clinical trial in advanced biliary cancers reported a significant prolongation of median overall survival when gemcitabine was combined with cisplatin, compared to gemcitabine alone, establishing this combination as a global standard of care (3) . However, the median overall survival of patients treated with the combination, despite an advancement was only 11.7 months, and so the discovery of active new agents is an urgent priority for patients with advanced biliary cancer.
The RAS/RAF/extracellular regulated kinase (ERK) signaling pathway plays a central role in the regulation of many cellular processes, including proliferation, survival, differentiation, apoptosis, motility, and metabolism (4, 5) . This pathway is activated by a diverse group of extracellular signals, including growth factor receptors (eg, epidermal growth factor receptor EGFR).
Expression of EGFR has been validated to be enhanced in tumor samples from 39.2%~46.2% of patients with biliary cancers (6, 7) . Moreover, activating mutations of KRAS and BRAF can occur in biliary cancers, with reported incidences of 8 to 58% (8) suggesting that activation of the RAF/MAPK signaling pathway may be a key event in a significant proportion of biliary cancers. AZD6244 (Selumetinib, ARRY-142886; AstraZeneca) is a second-generation, potent, selective, orally available, and uncompetitive small molecule inhibitor of MEK1/2(10). Recent phase II data(11) using AZD6244 as monotherapy demonstrated a modest activity (12% RECIST response rate) and was well tolerated in patients with advanced biliary cancer, suggesting the feasibility of combination with other drugs.
Gemcitabine (2',2'-difluorodeoxycytidine) is a nucleoside analogue with activity against biliary cancer in several phase II studies (12) and has also been reviewed in another manuscript (13) .
Following uptake by nucleoside transporters, gemcitabine is phosphorylated to its active forms gemcitabine diphosphate (dFdCDP) and gemcitabine triphosphate (dFdCTP). The latter competes with deoxycytidine triphosphate for incorporation into DNA, resulting in chain termination and DNA strand breaks (14) . The cytotoxicity of gemcitabine may also stem from the inhibition of ribonucleotide reductase by dFdCDP (15) . Both of these mechanisms probably contribute to its cytotoxic action, although it is not presently known to what extent.
Although gemcitabine is often combined with targeted agents, a recent preclinical study demonstrated that combining AZD6244 with gemcitabine did not show enhanced activity in a pancreatic cancer model (16) . In a previous study we observed that treatment with AZD6244 depleted S phase cells in xenografts derived from pancreatic cancer cell lines (17) . Therefore we reasoned that delayed entry into S-phase during MEK inhibition will antagonize the effects of gemcitabine against biliary cancers, whereas treatment with MEK inhibitor following exposure to gemcitabine might enhance its effect through the inhibition of repopulation by surviving tumor cells. This was tested in the present paper using two recently-developed, patient-derived primary biliary cancer xenografts, supplemented by experiments using established cell lines. Cells were cultured at 37°C and 5% CO 2 atmosphere. Primary xenografts. OCIP55 was established from a distal bile duct primary tumor resected by Whipple pancreatectomy, and GB1 was established from ascites fluid taken from a patient with advanced peritoneal metastases from a primary gallbladder cancer. On histological examination, these primary xenografts showed typical adenocarcinoma features ( Supplementary Fig.S1 ).
Material and Methods

Cell
Mutational analysis by the Sequenom MassARRAY (San Diego, CA), using the laboratorydeveloped PMH Solid Tumor Panel (Molecular Diagnostics Laboratory, University Health Network), did not identify actionable mutations in these samples, although K-ras G12D mutations were identified in the EGI-1and TFK-1 cell lines.
Xenografts used in this study were 4~6 passages for OCIP55 and 2~4 passages for GB1. Drug treatment commenced after 4~6 weeks of tumor growth. Tumor models from human cancer cell lines were also set up to test the effect of drug treatments. Flow cytometric analysis. Single-cell suspensions were prepared by an enzymatic technique as described previously (17), labeled with Alexa 488 azide obtained from Molecular Probes, Invitrogen, Eugene OR, by copper-catalyzed click chemistry and then stained with the DNAspecific dye DAPI at 1 μg/ml for 30 min. A Gallios flow cytometer (Beckman Coulter) was used for data acquisition. Cell cycle analysis was done using ModFit LTTM (Verity, Topsham, ME), and FCS3 Express (Denovo software) was used to analyze the EdU uptake.
Immunofluorescence staining. Frozen sections cut from tumor tissue were fixed in 3.7% formaldehyde for 15 min, and then incubated with EdU reaction cocktail (Click-iT® EdU Alexa Fluor® 647 Imaging Kit, Molecular Probes, Invitrogen, OR, USA)) for 30min, followed by incubation with primary rabbit anti-pERK1/2 antibody (1:50, Cell Signaling) and secondary FITC-conjugated anti-rabbit antibody. Control samples without EdU reaction and primary antibody exposure showed no specific staining. All sections were counterstained with DAPI to outline the nuclear area. Entire sections were imaged at 1μm resolution using a laser scanning system (TISSUEscope; Biomedical Photometrics), and composite images of regions of interest were imaged at higher resolution (magnification×20), using a conventional fluorescence microscope and scanning stage (BX50; Olympus Corporation). Uncompressed TIFF images (8-bit) were acquired for analysis. Analysis of plasma and tumor AZD6244 concentrations. AZD6244 concentrations in plasma and tumor samples were measured using a high performance liquid chromatography-mass spectrometry/mass spectrometry (HPLC-MS/MS) technique, as described previously (19) . Plasma samples were extracted by protein precipitation in acetonitrile. Homogenized tumor samples were obtained by liquid-liquid extraction with methyl tertbutylether (MTBE). Following centrifugation, the supernatants were evaporated to dryness using the Universal Vacuum System (Thermo Electron Corp., Milford, MA) and then dissolved again in HPLC mobile phase.
Separation was carried out using a reversed-phase HyperClone BDS C18 column (5 μm, 50 x 2.0 mm, Phenomenex, Torrance, CA) and a gradient mobile phase containing water/acetonitrile/formic acid. Peaks were detected using API3200 tandem mass spectrometry (Applied Biosystem/MDS Sciex, Streetsville, Ontario, Canada). After 55 minutes (determined by preliminary dynamic 18 F-FLT PET uptake experiments), the mice were anesthetized and underwent PET imaging for 10min using a microPET Focus 220 scanner (Siemens Medical Solutions), followed by a subsequent CT scan using a GE eXplore Locus Ultra microCT scanner (GE Healthcare) for anatomical reference. Reconstructed PET and CT data were co-registered and 2D regions of interest (ROI) were hand drawn to fit the primary tumor according to the CT and PET data sets. The standardized uptake value (SUV) was obtained by using the SUV of the most intense pixel in the tumor regions and normalized with the corresponding muscle SUVmean value from the same mouse.
Statistical methods. The statistical significance of differences in numerical data between multiple groups was evaluated with a one-way ANOVA test with Tukey's comparison post test, using Prism software (GraphPad). All statistical tests were 2-tailed. P < 0.05 was considered statistically significant.
Results
Cell cycle effects of AZD6244 and their relation to gemcitabine sensitivity in vitro.
Preliminary experiments were done to investigate the cell cycle effects of MEK inhibition, the recovery of S-phase entry following drug washout, and the effects on gemcitabine sensitivity in vitro, using EGI-1 and TFK-1 biliary cancer cell lines. Exposure to AZD6244 concentrations of 1μM and greater resulted in a decrease in ERK phosphorylation and increase in the expression of p27 Kip1 , but not p21 Cip1 (Fig. 1A) . Cell cycle analysis following 24-hour exposure to AZD6244 showed a dose-dependent increase in the percentage of cells in G1, with a corresponding reduction in S-phase cells and in EdU labeling (Fig. 1B and supplementary Fig.S2 ). When cells treated with 1μM AZD6244 for 24h were placed in drug-free medium, re-entry into S-phase was delayed by approximately 15 hours, following which cell cycle distribution and EdU uptake returned to control values ( Fig.2 and supplementary Fig.S3 ).
Next we determined the sensitivity of EGI-1 and TFK-1 cells to gemcitabine, using a commercial 
plate reader. The IC50 of EGI-1 cells to gemcitabine was 0.051± 0.012μM and that of TFK-1 to gemcitabine was 0.45±0.35μM, which is consistent with previous reports for these cells (21) (22) (23) .
Two combination protocols were evaluated in cell culture: sequential treatment consisting of 24 h exposure to 1 μM AZD6244 followed by incubation in drug-free medium for 24 h, then 24 h treatment with 0-10μM gemcitabine, or simultaneous exposure to 1μM AZD6244 and gemcitabine for 24 hr. Using the MTS assay, sequential treatment (IC50=0.09±0.04μM) but not simultaneous treatment (IC50=2.02±0.91μM) enhanced the inhibition of TFK-1 cell proliferation compared to gemcitabine alone. A similar result was observed with EGI-1 cells (Fig.3A) . Since TFK-1 cells are relatively gemcitabine-resistant the sensitizing effect of pre-treatment with AZD6244 was investigated further, using a flow cytometric cell viability assay based on combined measurement of mitochondrial membrane potential and surface membrane integrity as previously described (24) . Compared to gemcitabine alone, sequential treatment showed enhanced cytotoxic effect (P<0.05), whereas no significant difference was observed with the simultaneous combination ( Fig.3B and supplementary FigS4) . Similarly, using a clonogenic assay, we observed significant loss of viability in cells pre-exposed to 1μM AZD6244 prior to gemcitabine treatment (p<0.01), whereas there was no significant enhancement using simultaneous treatment. AZD6244 alone did not significantly affect clonogenic survival of TFK-1 cells (Fig.3C) .
Pharmacodynamic and pharmacokinetic analysis of AZD6244 in vivo
To determine the optimal combination schedule in vivo, we first investigated the relationship between the pharmacokinetics of AZD6244 in OCIP 55 xenografts and the pharmacodynamic effects on ERK pathway inhibition and S-phase progression. As illustrated in Fig.4A 
showed that 48 h treatment with AZD6244 blocked the ERK pathway and inhibited EdU uptake.
These effects persisted for 24h after the last dose of AZD6244, when phosphorylated ERK returned to pretreatment levels. The recovery of EdU uptake did not occur until the 48h time point, when it appeared to overshoot the value of the untreated control. A similar pattern was seen using flow cytometry to monitor EdU uptake during recovery from AZD6244 (Fig.4D ).
Functional imaging of thymidine uptake using 18 F-FLT PET would allow the recovery kinetics following MEK inhibition to be studied directly in biliary cancer patients, which is the goal of this research. Therefore, we applied this technique to a separate group of mice bearing OCIP55 xenografts, treated with AZD6244 according to the same protocol. As shown in Fig.5 , tracer uptake was readily detected in the flanks of the tumor-bearing mice, and showed a significant decrease for 24hr after the last drug dose, recovering to untreated control values at 48hr, similar to the results obtained using EdU.
To explore the correlation between these pharmacodynamic effects and the drug levels, LC-MS was used to measure AZD6244 in plasma and tumor tissue. As shown in Fig.4E , a mean plasma concentration of 2403ng/ml was obtained 4 hours after the final dose of AZD6244 treatment, with a rapid decrease at the later time points that is consistent with the published data for this compound (10, 25) . In contrast, although the concentration of AZD6244 in tumor tissue was lower than the plasma level at the 4hr time point, the drug was retained for longer in tumor tissue and showed the expected inverse relationship to ERK phosphorylation. Thus, the 48hr lag period between the last drug dose and re-entry into S-phase appears to be explained partly by the time needed for reactivation of the ERK pathway, and partly by a latent period in G1 following the recovery of ERK signaling, similar to that seen following drug exposure in vitro (Fig.2) . Based on these observations, we reasoned that gemcitabine would be relatively ineffective if given concurrently with AZD6244, or within 48hr of the last dose.
Inhibitory effect of sequential combination of AZD6244 and gemcitabine on tumor growth in vivo
A preliminary study showed that long-term single agent treatment with AZD6244 (25mg/kg bid) or gemcitabine (100mg/kg biweekly) was well tolerated (Supplementary Fig.S5 ). AZD6244 monotherapy showed modest antitumor effects in all four models, whereas gemcitabine showed slight antitumor effect against TFK-1, but robust activity against EGI-1 xenografts, similar to the differential effects seen in vitro, and modest activity in the two primary xenograft models.
Two combination schedules were designed using the same total doses of gemcitabine and AZD6244 in four day treatment cycles (Fig. 6A) . In schedule A, gemcitabine was given immediately after the final dose of 48hr treatment with AZD6244, followed by a 48hr treatmentfree period prior to the next cycle ("simultaneous dosing"); in schedule-B, gemcitabine was given 48hours after the final dose of AZD6244, following which treatment with AZD6244 was restarted ("sequential dosing"). Both treatment schedules were well tolerated with no treatmentrelated deaths, and there were no significant differences in animal weight ( Supplementary   Fig.S6A ). Weekly blood counts were done in the groups bearing OCIP55 xenografts ( Supplementary Fig. S6B ). Although there was a modest decrease in total white cell count in mice treated with each of the drug combination schedules, there was no significant difference between them. As shown in Fig. 6B and Supplementary Fig. S7 , sequential treatment markedly inhibited tumor growth in all four models, whereas simultaneous dosing was not significantly more effective that gemcitabine monotherapy with the exception of TFK-1, which was refractory to gemcitabine monotherapy but relatively sensitive to AZD6244.
Discussion
The ERK pathway is frequently activated in cancer due to genetic alterations in its regulation, and it has the potential to promote tumor growth and treatment resistance through multiple downstream effector pathways. Currently available MEK inhibitors have shown quite modest single agent activity against a range of tumor types, including biliary cancers, and it is therefore logical to consider incorporating these agents into combinations with standard chemotherapy drugs in the hope of obtaining more active and well tolerated combinations. However, because the ERK pathway plays a major role in cell cycle progression, there is a theoretical possibility that the sensitivity to S-phase specific agents like gemcitabine or 5-fluorouracil would be reduced during MEK inhibition. On the other hand, the administration of agents that inhibit tumor cell proliferation following treatment with chemotherapy might enhance its effect by suppressing repopulation by viable tumor cells during the interval between chemotherapy courses (26) . This is addressed in the present paper. pathway plays a dominant, but not critical role in S-phase progression of these cells. Recovery of cell cycle progression was delayed by 15 hr following removal of AZD6244, suggesting that the cell cycle was blocked at a checkpoint midway through G1, rather than at the G1/S boundary.
Three different assays were used to study the schedule dependence of AZD6244 plus gemcitabine drug combinations: a standard MTS assay, a flow cytometry assay combining measurement of mitochondrial membrane potential and surface membrane integrity, and a clonogenic survival assay. A similar result was obtained with all of these methods, with concurrent treatment having no significant effect compared to gemcitabine alone, whereas when gemcitabine treatment was delayed for 24 hr after AZD6244 removal, there was significant enhancement of its effect.
Similar to the in vitro effects, the biliary cancer xenografts showed cell cycle arrest during treatment with AZD6244, with re-entry into S-phase delayed by approximately 48hr following the last dose. This effect was readily detected using Consistently in all four models tested, tumor growth control was improved when treatment with AZD6244 commenced immediately after gemcitabine and was discontinued 48hr prior to the next gemcitabine treatment, whereas when gemcitabine was given after AZD6244, the effect was sub-additive. We think it likely that this result can be translated into the clinic to treat biliary cancer patients, who are urrently treated with gemcitabine plus low dose cisplatin. Preliminary results using our two primary biliary cancer models suggest that tumor growth control can be further enhanced when AZD6244 is given following cycles of gemcitabine plus low dose cisplatin ( Supplementary Fig.S8 ).
In summary, the data presented in this paper strongly point to the importance of testing the sequence effects when combining MEK inhibitors with gemcitabine to treat biliary cancer patients (and potentially other tumor types); suggest the potential to incorporate MEK inhibitors into protocols combining gemcitabine, and they point to the utility of Material and Methods. In the clonogenic assay, the survival fraction was normalized by the control group. Data were presented as mean ± SD of at least three independent experiments.
Representative images shown in FigS4. 
